keyword
MENU ▼
Read by QxMD icon Read
search

sitagliptin

keyword
https://www.readbyqxmd.com/read/29770541/effect-of-short-term-treatment-with-sitagliptin-or-glibenclamide-on-daily-glucose-fluctuation-in-drug-na%C3%A3-ve-japanese-patients-with-type-2-diabetes-mellitus
#1
Ryo Suzuki, Jun-Ichi Eiki, Takashi Moritoyo, Kenichi Furihata, Akira Wakana, Yukari Ohta, Shigeru Tokita, Takashi Kadowaki
AIMS: To compare the effect of a dipeptidyl peptidase-4 inhibitor (DPP4-i) and a sulfonylurea (SU) on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus (T2DM). MATERIALS AND METHODS: Fifty-three drug-naïve Japanese patients with T2DM (HbA1c of 7.0% to 9.0% and fasting plasma glucose of 6.1 mmol/L or higher) were randomly assigned to either sitagliptin 50 mg q.d. or glibenclamide 2.5 mg per day (given in divided doses) in a 1:1 ratio...
May 17, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29766634/semaglutide-induces-weight-loss-in-subjects-with-type-2-diabetes-regardless-of-baseline-bmi-or-gastrointestinal-adverse-events-in-sustain-1-5-trials
#2
Bo Ahrén, Stephen L Atkin, Guillaume Charpentier, Mark L Warren, John Ph Wilding, Sune Birch, Anders Gaarsdal Holst, Lawrence A Leiter
AIMS: Semaglutide, a new once-weekly glucagon-like peptide 1 analogue for the treatment of type 2 diabetes, demonstrated superior reductions in HbA1c and superior weight loss (by 2.3-6.3 kg) versus different comparators across the SUSTAIN 1-5 trials; the contributing factors to weight loss are not established. This post hoc analysis assessed the effect of baseline body mass index (BMI), and of occurrence of nausea and/or vomiting, on semaglutide-induced weight loss. MATERIALS AND METHODS: Subjects with inadequately controlled type 2 diabetes (drug-naïve or on background treatment) were randomized to subcutaneous semaglutide 0...
May 15, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29762878/risk-of-hypoglycemia-after-concomitant-use-of-antidiabetic-antihypertensive-and-antihyperlipidemic-medications-a-database-study
#3
Masahiko Gosho
Hypoglycemia is the most important complication of antidiabetic medications. Most patients with diabetes mellitus take multiple medications. In this study, we explored clinical drug-drug interactions that result in hypoglycemia by analyzing the Japanese Adverse Drug Event Report (JADER) database. The primary outcome was the report of hypoglycemia. The Norén and Gosho methods, which quantitatively measure the discrepancy between the observed and expected number of adverse events under the combination of 2 drugs, were used as the criteria for detecting drug-drug interactions...
May 15, 2018: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/29761171/coding-variants-in-pnpla3-and-tm6sf2-are-risk-factors-for-hepatic-steatosis-and-elevated-serum-alanine-aminotransferases-caused-by-a-glucagon-receptor-antagonist
#4
Cristina B Guzman, Suman Duvvuru, Anthony Akkari, Pallav Bhatnagar, Chakib Battioui, Wendra Foster, Xiaotian Michelle Zhang, Sudha S Shankar, Mark A Deeg, Naga Chalasani, Thomas A Hardy, Christof M Kazda, Sreekumar G Pillai
LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated alanine aminotransferases (ALTs) associated with LY2409021. Patients participated in a 6-week placebo-controlled trial (I1R-MC-GLDI [GLDI], n = 246) and a 52-week placebo- and active comparator-controlled trial (I1R-MC-GLDJ [GLDJ], n = 158). GLDJ had endpoints at 6 months, including measures of hepatic fat fraction (HFF) by magnetic resonance imaging...
May 2018: Hepatology Communications
https://www.readbyqxmd.com/read/29760346/effect-of-sitagliptin-on-coronary-flow-reserve-assessed-by-magnetic-resonance-imaging-in-type-2-diabetic-patients-with-coronary-artery-disease
#5
Keishi Moriwaki, Tetsushiro Takeuchi, Naoki Fujimoto, Toshiki Sawai, Yuichi Sato, Naoto Kumagai, Jun Masuda, Shiro Nakamori, Masaki Ishida, Norikazu Yamada, Mashio Nakamura, Hajime Sakuma, Masaaki Ito, Kaoru Dohi
BACKGROUND: The present study was conducted to assess the cardiovascular effects of dipeptidyl peptidase-4 inhibitors (DPP4i) on coronary flow reserve (CFR), left ventricular (LV) function and endothelial function of the peripheral artery by comparison with those of α-glucosidase inhibitors (αGI) in patients with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD).Methods and Results:We randomly assigned 30 patients with T2DM and CAD to receive either sitagliptin or voglibose, and 28 patients (age 69±9 years, 75% male, hemoglobin A1c [HbA1c] 6...
May 12, 2018: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/29756388/semaglutide-for-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#6
Panagiotis Andreadis, Thomas Karagiannis, Konstantinos Malandris, Ioannis Avgerinos, Aris Liakos, Apostolos Manolopoulos, Eleni Bekiari, David R Matthews, Apostolos Tsapas
AIM: To assess the efficacy and safety of semaglutide, a recently approved glucagon-like peptide 1 receptor agonist (GLP-1 RA) for type 2 diabetes. METHODS: We searched major electronic databases and grey literature sources for randomised controlled trials comparing semaglutide with placebo or other antidiabetic agents. Primary outcome was change from baseline in HbA1c . Secondary endpoints included change from baseline in body weight, blood pressure, heart rate, and incidence of hypoglycaemia, gastrointestinal adverse effects, pancreatitis and diabetic retinopathy...
May 13, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29754067/enantiomeric-impurity-analysis-using-circular-dichroism-spectroscopy-with-united-states-pharmacopeia-liquid-chromatographic-methods
#7
Douglas Kirkpatrick, Margaret Fain, Jingyue Yang, Michael Trehy
Over 300 chiral drug substances lack official United States Pharmacopeia (USP) methods for the enantiomeric purity determination. Because enantiomeric analysis typically requires specialized methods for each drug compound, developing protocols for each of these 300+ substances would be an expensive and laborious endeavor. Alternatively, if a detector capable of determining the enantiomeric composition without chiral separation could be used with certain drug compounds, this could be implemented relatively rapidly into official testing monographs...
April 24, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29748368/cardiovascular-effects-of-new-oral-glucose-lowering-agents-dpp-4-and-sglt-2-inhibitors
#8
REVIEW
André J Scheen
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would be considered a major advance, as recently reported with liraglutide and semaglutide, 2 glucagon-like peptide-1 receptor agonists, and with empagliflozin and canagliflozin, 2 SGLT-2 (sodium-glucose cotransporter type 2) inhibitors, but not with DPP-4 (dipeptidyl peptidase-4) inhibitors. The present review is devoted to CV effects of new oral glucose-lowering agents...
May 11, 2018: Circulation Research
https://www.readbyqxmd.com/read/29744818/real-world-clinical-effectiveness-and-cost-savings-of-liraglutide-versus-sitagliptin-in-treating-type-2-diabetes-for-1-and-2-years
#9
Qian Li, Rahul Ganguly, Michael L Ganz, Cory Gamble, Tam Dang-Tan
INTRODUCTION: This study compared the clinical and economic outcomes of long-term use of liraglutide versus sitagliptin for the treatment of type 2 diabetes (T2DM) in real-world practice in the USA. METHODS: We identified adult patients (≥ 18 years old) with T2DM who initiated liraglutide or sitagliptin in 2010-2014 using a large claims database. Quarterly glycemic control measures and annual healthcare costs were assessed during the 1st and 2nd years of persistent medication use...
May 9, 2018: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/29740221/effect-of-sitagliptin-on-hepatic-histological-activity-and-fibrosis-of-nonalcoholic-steatohepatitis-patients-a-1-year-randomized-control-trial
#10
Shahinul Alam, Jhumur Ghosh, Golam Mustafa, Mohammad Kamal, Nooruddin Ahmad
Background/purpose: Dipeptidyl peptidase 4 (DPP-4) expression is directly associated with hepatic lipogenesis and liver injury in nonalcoholic steatohepatitis (NASH). This study has been designed to elucidate the histological improvement of NASH with the DPP-4 inhibitor sitagliptin. Materials and methods: In this open-label randomized control trial, paired liver biopsy was taken from 40 NASH patients. Sitagliptin 100 mg was given once daily to the SL group and no sitagliptin was given to the L group for 1 year...
2018: Hepatic Medicine: Evidence and Research
https://www.readbyqxmd.com/read/29716857/development-of-a-rapid-resolution-hplc-method-for-the-quantitative-determination-of-sitagliptin-in-human-plasma
#11
Qaiser Iqbal, Sajid Bashir, Syed Umer Jan, Muhammad Zubair Malik, Iftikhar Afzal, Ayesha Khalid
A new high performance liquid chromatography (HPLC) method for the quantitative determination of sitagliptin in human plasma was developed and validated for pharmacokinetics study. The plasma was spiked with the internal standard (Salbutamol, IS), extracted with trichloro acetic acid. The extracted analyte was injected into a Symmetry® ODS C18 column (250mm×4.5mm, 5m) and the flourometric detector was operated at 267nm for excitation and 575nm for emission. The mobile phase consisting of Potassium dihydrogen phosphate buffer pH (4...
May 2018: Pakistan Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29698678/citrus-bioflavonoids-possess-dipeptidyl-peptidase-4-inhibition-activity-similar-to-gliptin-antidiabetic-medication
#12
Ankit Gupta, Glenn A Jacobson, John R Burgess, Herbert F Jelinek, David S Nichols, Christian K Narkowicz, Hayder A Al-Aubaidy
This study demonstrates the Dipeptidyl peprtidase-4 (DPP-4) inhibition activity of citrus bioflavonoid nutraceuticals as compared to known gliptins. Citrus bioflavonoid standards and three commercially available citrus bioflavonoid supplements (Thompson's Super Bioflavonoid Complex® (SB), Ethical Nutrient Citrus Plus Vitamin C® (EN), and Country Life Citrus Bioflavonoid & Rutin® (CB)) were considered in this study. Ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) analysis was undertaken to identify the citrus bioflavonoids present in each supplement and the DPP-4 inhibitory activity was determined using the DPP-4 fluorometric assay...
April 23, 2018: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29697017/high-fat-diet-induces-depression-like-behaviour-in-mice-associated-with-changes-in-microbiome-neuropeptide-y-and-brain-metabolome
#13
Ahmed M Hassan, Giulia Mancano, Karl Kashofer, Esther E Fröhlich, Andrija Matak, Raphaela Mayerhofer, Florian Reichmann, Marta Olivares, Audrey M Neyrinck, Nathalie M Delzenne, Sandrine P Claus, Peter Holzer
OBJECTIVES: The biological mechanisms linking diet-related obesity and depression remain unclear. Therefore, we examined the impact of high-fat diet (HFD) on murine behaviour, intestinal microbiome, brain metabolome, neuropeptide Y (NPY) expression, and dipeptidyl peptidase-4 (DPP-4) activity. METHODS: Male C57Bl/6J mice were fed an HFD (60 kJ% from fat) or control diet (12 kJ% from fat) for 8 weeks, followed by behavioural phenotyping. Caecal microbiome was analysed by 16S rDNA sequencing, brain metabolome by 1 H nuclear magnetic resonance, NPY expression by PCR and immunoassay, and dipeptidyl peptidase-4 (DPP-4) activity by enzymatic assay...
April 26, 2018: Nutritional Neuroscience
https://www.readbyqxmd.com/read/29689469/extractability-mediated-stability-bias-and-hematocrit-impact-high-extraction-recovery-is-critical-to-feasibility-of-volumetric-adsorptive-microsampling-vams-in-regulated-bioanalysis
#14
Iris Xie, Yang Xu, Melanie Anderson, Ming Wang, Lingling Xue, Sheila Breidinger, Dina Goykhman, Eric J Woolf, Kevin P Bateman
Volumetric absorptive microsampling (VAMS), a new microsampling technique, was evaluated for its potential in supporting regulated bioanalysis. Our initial assessment with MK-0518 (raltegravir) using a direct extraction method resulted in 45-52% extraction recovery, significant hematocrit (Ht) related bias, and more importantly, unacceptable stability (>15% bias from nominal concentration) after 7-day storage. Our investigation suggested that the observed biases were not due to VAMS absorption, sampling techniques, lot-to-lot variability, matrix effect, and/or chemical stability of the compound, but rather the low extraction recovery...
April 5, 2018: Journal of Pharmaceutical and Biomedical Analysis
https://www.readbyqxmd.com/read/29687620/semaglutide-as-a-therapeutic-option-for-elderly-patients-with-type-2-diabetes-pooled-analysis-of-the-sustain-1-5-trials
#15
Mark Warren, Louis Chaykin, David Trachtenbarg, Gurudutt Nayak, Nelun Wijayasinghe, Bertrand Cariou
This pooled analysis evaluated the efficacy and safety of semaglutide vs comparators in non-elderly (<65 years) and elderly (≥65 years) patients with type 2 diabetes (T2D) across the SUSTAIN 1-5 trials. Patients were randomised to once-weekly subcutaneous semaglutide (0.5 or 1.0 mg) vs placebo, sitagliptin, exenatide or insulin. Primary objective was change in HbA1c ; secondary objectives were change in body weight and safety. Mean HbA1c decreased from baseline by 1.2-1.5% and 1.5-1.9% vs 0.0-0.9% (non-elderly, n=3,045) and by 1...
April 23, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29682739/bullous-pemphigoid-induced-by-dipeptidyl-peptidase-4-inhibitors-eight-cases-with-clinical-and-immunological-characterization
#16
Irene García-Díez, Marta Ivars-Lleó, Daniel López-Aventín, Norito Ishii, Takashi Hashimoto, Pilar Iranzo, Ramon M Pujol, Agustín España, Josep E Herrero-Gonzalez
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have increasingly been identified as causative agents of bullous pemphigoid. The clinical and immunological characteristics of this pemphigoid variant are still unclear. The objective of our study was to analyze the clinical and immunological features of patients with pemphigoid induced by DPP-4 inhibitors. METHODS: All patients diagnosed with DPP-4 inhibitor-associated bullous pemphigoid at dermatology departments in three Spanish centers during the period 2013 to 2015 were included...
April 23, 2018: International Journal of Dermatology
https://www.readbyqxmd.com/read/29679391/cardiovascular-effects-of-sitagliptin-an-anti-diabetes-medicine
#17
REVIEW
Yi Zhou, Zhiying Guo, Wenjing Yan, Wen Wang
Dipeptidyl-peptidase-4 (DPP-4) inhibitors, as the most recent available anti-diabetic agents, were generally used in clinical treatment of type 2 diabetes (T2DM). In addition to anti-diabetic effects, the five most widely used DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin) also exert cardiovascular protective effects. In recent years, increasing studies suggest that sitagliptin shows pleiotropic impacts towards the cardiovascular system either with or without diabetes...
April 21, 2018: Clinical and Experimental Pharmacology & Physiology
https://www.readbyqxmd.com/read/29671284/comparative-cardiovascular-risks-of-dipeptidyl-peptidase-4-inhibitors-analyses-of-real-world-data-in-korea
#18
Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, Jinhee Lee, Hansol Choi, Hyeon Chang Kim, Dae Jung Kim
BACKGROUND AND OBJECTIVES: To compare cardiovascular disease (CVD) risk associated with 5 different dipeptidyl peptidase-4 inhibitors (DPP-4is) in people with type 2 diabetes. METHODS: We identified 534,327 people who were newly prescribed sitagliptin (n=167,157), vildagliptin (n=67,412), saxagliptin (n=29,479), linagliptin (n=220,672), or gemigliptin (n=49,607) between January 2013 and June 2015 using the claims database of the Korean National Health Insurance System...
February 27, 2018: Korean Circulation Journal
https://www.readbyqxmd.com/read/29670074/recovery-from-diabetic-macular-edema-in-a-diabetic-patient-after-minimal-dose-of-a-sodium-glucose-co-transporter-2-inhibitor
#19
Hideyuki Yoshizumi, Tetsushi Ejima, Tetsuhiko Nagao, Masanori Wakisaka
BACKGROUND Diabetic macular edema (DME) causes serious visual impairments in diabetic patients. The standard treatments of DME are intra-vitreous injections of corticosteroids or anti-vascular endothelial growth factor antibodies and pan-photocoagulation. These treatments are unsatisfactory in their effects and impose considerable physical and economic burdens on the patients. CASE REPORT A 63-year-old woman was diagnosed as type 2 diabetes with retinopathy 7 years ago. Before the initiation of an SGLT2 inhibitor, the dipeptidyl peptidase-4 inhibitor, sitagliptin (50 mg daily), and metformin (250 mg dai- ly) were used for her glycemic control...
April 19, 2018: American Journal of Case Reports
https://www.readbyqxmd.com/read/29666090/rare-case-of-chorea-hyperglycaemia-basal-ganglia-c-h-bg-syndrome
#20
Sajjad Ahmad, Priya Mohan Babu, Lavanya Shenbagaraj, Lindsay George
An 83-year-old woman presented with acute-onset haemichorea and haemiballism particularly affecting the left side of the body. She was known to have type 2 diabetes, which was poorly controlled with sitagliptin. She was hyperglycaemic but not ketotic or acidotic. After she was started on insulin and good glycaemic control was achieved, her abnormal movements dramatically improved. MRI of the brain showed a T1-weighted hyperintense lesion on the right basal ganglia, which is typical of chorea-hyperglycaemia-basal ganglia syndrome...
April 17, 2018: BMJ Case Reports
keyword
keyword
28643
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"